Variation in the Expression Levels of IL6, IL8, STAB1, YKL40, and TLR7 Genes in Monocytes in Patients with Prostate Cancer

Aim. To analyze changes in gene expression of S100 calcium-binding protein A8 (S100A8), S100 calcium-binding protein A9 (S100A9), S100 calcium-binding protein A12 (S100A12), chitinase-3-like protein 1 (YKL40), chitinase3-like protein 2 (YKL39), stabilin 1 (STAB1), tumor necrosis factor α (TNFα), interleukin-1 beta (IL1B), interleukin-1 receptor antagonist (IL1RN), interleukin-6 (IL6), interleukin-10 (IL10), interleukin-12 subunit A (IL12A), C-X-C motif chemokine ligand 8 (IL8), C–C motif chemokine ligand 18 (CCL18), Toll-like receptor 2 (TLR2), Toll-like receptor 4 (TLR4), Toll-like receptor 7 (TLR7), mannose receptor C-type 1 (MRC1), neuropilin-1 (NRP1), transforming growth factor beta-1 (TGFβ1), and colony-stimulating factor 1 (CSF1) in monocytes of prostate cancer (PCa) patients and healthy men.

Materials and methods. The study included 35 patients with stage II–IV PCa and 11 healthy men. Monocytes were obtained from peripheral blood by magnetic sorting. Gene expression analysis and ROC analysis were performed, and the Pearson’s correlation was applied.

Results. In patients with PCa, decreased expression of the IL8 (p = 0.0001, q = 0.002) and YKL40 (p = 0.002, q = 0.017) genes was observed after the Benjamini – Hochberg correction. In contrast, TLR7 (p = 0.0054, q = 0.031) gene expression was significantly increased two-fold in the PCa group. The ROC analysis demonstrated the ability to statistically significantly differentiate patients with PCa.

Conclusion. The study revealed decreased expression of IL8 and YKL40 in monocytes obtained from prostate cancer patients, whereas TLR7 expression was elevated two-fold. The ROC analysis results confirm the diagnostic potential of these markers for differentiating prostate cancer patients.

1. Xue R., Zhang Q., Cao Q., Kong R., Xiang X., Liu H. et al. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Nature. 2022;612(7938):141–147. DOI: 10.1038/s41586-022-05400-x.

2. Qiu Z., Li S., Luo M., Zhu S., Wang Z., Jiang Y. Detection of differentially expressed genes in spatial transcriptomics data by spatial analysis of spatial transcriptomics: A novel method based on spatial statistics. Front. Neurosci. 2022;16:1086168. DOI: 10.3389/fnins.2022.1086168.

3. Cavassani K.A., Meza R.J., Habiel D.M., Chen J.F., Montes A., Tripathi M. et al. Circulating monocytes from prostate cancer patients promote invasion and motility of epithelial cells. Cancer Med. 2018;7(9):4639–4649. DOI: 10.1002/cam4.1695.

4. Sharma J., Gray K.P., Harshman L.C., Evan C., Nakabayashi M., Fichorovaст R. et al. Elevated IL-8, TNF-α, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival. Prostate. 2014;74(8):820–828. DOI: 10.1002/pros.22788.

5. Kattan M.W., Shariat S.F., Andrews B., Zhu K., Canto E., Matsumoto K. et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J. Clin. Oncol. 2003;21(19):3573–3579. DOI: 10.1200/JCO.2003.12.037.

6. David J.J.W., Catherine W., Angela S., Pamela J.M. Multi-faceted roles for CXC-chemokines in prostate cancer progression. Front. Biosci. (Landmark Ed.). 2008;13(12):4595–4604. DOI: 10.2741/3025.

7. Palano M.T., Gallazzi M., Cucchiara M., Dehò F., Capogrosso P., Bruno A. et al. The tumor innate immune microenvironment in prostate cancer: an overview of soluble factors and cellular effectors. Explor. Target Antitumor. Ther. 2022;3(5):694– 718. DOI: 10.37349/etat.2022.00108.

8. Christensson A., Björk T., Nilsson O., Dahlén U., Matikainen M.T., Cockett A.T. et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J. Urol. 1993;150(1):100–105. DOI: 10.1016/s0022-5347(17)35408-3.

9. Väisänen M.R., Väisänen T., Jukkola-Vuorinen A., Vuopala K.S., Desmond R., Selander K.S. et al. Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors. Prostate. 2010;70(8):817–824. DOI: 10.1002/pros.21115.

10. Zhao H., Zhang X., Shi Z., Guo B., Zhang W., He K. et al. Identification of a prognostic signature model with tumor microenvironment for predicting disease-free survival after radical prostatectomy. J. Cancer. 2021;12(8):2371–2384. DOI: 10.7150/jca.51173.

11. Mustafina I.A., Markelov V.A., Solntsev V.A., Danilko K.V., Zagidullin N.Sh. Different levels of microRNA expression (miR-30c-5p, miR-221-3p and miR-375-3p) in patients with heart failure with preserved and reduced ejection fraction. Yakut Medical Journal. 2024;4(88):12–15. DOI: 10.25789/YMJ.2024.88.03.

12. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 2008;3(6):1101– 1108. DOI: 10.1038/nprot.2008.73.

13. Olivera I., Sanz-Pamplona R., Bolaños E., Rodriguez I., Etxeberria I., Cirella A. et al. A therapeutically actionable protumoral axis of cytokines involving IL-8, TNFα, and IL-1β. Cancer Discov. 2022;12(9):2140–2157. DOI: 10.1158/2159-8290.CD-21-1115.

14. Cavassani K.A., Meza R.J., Habiel D.M., Chen J.F., Montes A., Tripathi M. et al. Circulating monocytes from prostate cancer patients promote invasion and motility of epithelial cells. Cancer Med. 2018;7(9):4639–4649. DOI: 10.1002/cam4.1695.

15. Zhao T., Su Z., Li Y., Zhang X., You Q. Chitinase-3 like-protein-1 function and its role in diseases. Signal Transduct. Target Ther. 2020;5(1):201. DOI: 10.1038/s41392-020-00303-7.

16. De Marcken M., Dhaliwal K., Danielsen A.C., Gautron A.S., Dominguez-Villar M. TLR7 and TLR8 activate distinct pathways in monocytes during RNA virus infection. Sci. Signal. 2019;12(605):eaaw1347. DOI: 10.1126/scisignal.aaw1347.

17. Yu S.H., Zheng Q., Esopi D., Macgregor-Das A., Luo J., Antonarakis E.S. et al. A paracrine role for IL6 in prostate cancer patients: lack of production by primary or metastatic tumor cells. Cancer Immunol. Res. 2015;3(10):1175–1184. DOI: 10.1158/2326-6066.CIR-15-0013.

18. Orange S.T., Leslie J., Ross M., Mann D.A., Wackerhage H. The exercise IL-6 enigma in cancer. Trends Endocrinol. Metab. 2023;34(11):749–763. DOI: 10.1016/j.tem.2023.08.001.

19. Lee W., Park S.Y., Yoo Y., Kim S.Y., Kim J.E., Kim S.W. et al. Macrophagic stabilin-1 restored disruption of vascular integrity caused by sepsis. Thromb. Haemost. 2018;118(10):1776– 1789. DOI: 10.1055/s-0038-1669477.